Continuum Clinical
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
SCIRIS ACQUIRES SOURCE HEALTH ECONOMICS
Global healthcare communications company SCIRIS is delighted to announce the acquisition of UK-based Source Health Economics – an agency specialising in health economics and outcomes research (HEOR).The development is the...
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...
Patient Centric Approaches for Rare and Ultra-Rare Diseases
Lawrence Bressler, Head of Value & Market Access, Global Rare Diseases at Chiesi, shares how Chiesi is revolutionizing the lives of people living with rare diseases on a global scale....
Genesis Research Insights & Evidence webinar 20 Oct: Reserve your place!
Join Priti Jhingran of Genesis Research and Tijana Ignjatovic of Market Access Transformation (MAT) for their webinar 'Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to...
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer
International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...
Genesis Research and Syapse combine forces to offer RWE and data to oncology innovators
Genesis Research is delighted to announce a strategic partnership with Syapse®, combining the expertise and resources of both companies to better serve clients that are developing new oncology innovations.
Virtual product launch planning: the ultimate playbook
We walk you through, step-by-step, how cross-functional teams can seamlessly work together and overcome the many obstacles associated with traditional product launches.